Literature DB >> 10442525

A double-blind, single-dose, crossover comparison of cetirizine, ebastine, epinastine, fexofenadine, terfenadine, and loratadine versus placebo: suppression of histamine-induced wheal and flare response for 24 h in healthy male subjects.

J A Grant1, L Danielson, J P Rihoux, C DeVos.   

Abstract

BACKGROUND: New H1-antagonists have become available, but there has been no comparison of their potency for inhibiting histamine in the skin.
METHODS: Cetirizine 10 mg, ebastine 10 mg, epinastine 20 mg, fexofenadine 60 mg, terfenadine 60 mg, loratadine 10 mg, or placebo was given to 14 healthy male volunteers in a double-blind, crossover randomized manner. Inhibition of the wheal and flare response to epicutaneous histamine phosphate (100 mg/ml) challenge was measured at 0, 0.5, 1, 2, 4, 6, 8, 10, 12, and 24 h after doses.
RESULTS: Epinastine inhibited the wheal and flare after 30 min. Cetirizine commenced acting at 1 h and was superior to other treatments. Ebastine was no better than placebo until 4 h, but was efficacious thereafter until 24 h. Terfenadine induced potent inhibition after 1 h and was superior to its metabolite fexofenadine. Loratadine was the least potent inhibitor. Inhibition of the flare response paralleled the patterns seen for wheals. The rank order for area under the curve (0-24 h) was cetirizine, epinastine, terfenadine, ebastine, fexofenadine, loratadine, and placebo.
CONCLUSIONS: The inhibition of histamine effects in the skin may be useful in predicting the clinical utility of newly introduced antihistamines in treating allergic disorders.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10442525     DOI: 10.1034/j.1398-9995.1999.00032.x

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  11 in total

Review 1.  New insights into the second generation antihistamines.

Authors:  G M Walsh; L Annunziato; N Frossard; K Knol; S Levander; J M Nicolas; M Taglialatela; M D Tharp; J P Tillement; H Timmerman
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 2.  Second-generation antihistamines: actions and efficacy in the management of allergic disorders.

Authors:  Larry K Golightly; Leon S Greos
Journal:  Drugs       Date:  2005       Impact factor: 9.546

3.  Comparison of on-site and photographic evaluations of the suppressive effects of cetirizine, loratadine, and fexofenadine on skin response to histamine lontophoresis: A double-blind, crossover study in healthy volunteers.

Authors:  Hidetaka Tsuda; Hirotsugu Takiwaki
Journal:  Curr Ther Res Clin Exp       Date:  2005-07

4.  Cetirizine: a review of its use in allergic disorders.

Authors:  Monique P Curran; Lesley J Scott; Caroline M Perry
Journal:  Drugs       Date:  2004       Impact factor: 9.546

5.  Twenty-four-hour activity and consistency of activity of levocetirizine and desloratadine in the skin.

Authors:  Ashok Purohit; Michel Melac; Gabrielle Pauli; Nelly Frossard
Journal:  Br J Clin Pharmacol       Date:  2003-10       Impact factor: 4.335

6.  H1 but not H2 histamine receptor activation contributes to the rise in skin blood flow during whole body heating in humans.

Authors:  Brett J Wong; Brad W Wilkins; Christopher T Minson
Journal:  J Physiol       Date:  2004-09-16       Impact factor: 5.182

7.  A comparison of ebastine 10 mg fast-dissolving tablet with oral desloratadine and placebo in inhibiting the cutaneous reaction to histamine in healthy adults.

Authors:  Rosa M Antonijoan; Consuelo García-Gea; Montserrat Puntes; Marta Valle; Ramon Esbri; Josep Fortea; Manuel J Barbanoj
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

8.  Randomized, single-blind, crossover comparison of two rupatadine tablet formulations on histamine-induced cutaneous response in healthy adult volunteers.

Authors:  Pingali Usharani; Maddireddi U R Naidu; B S Parthasarathy Reddy; Mohan Reddy
Journal:  Curr Ther Res Clin Exp       Date:  2007-11

9.  Ebastine overdose in a child.

Authors:  Luca Pecoraro; Giulia Paiola; Angelo Pietrobelli
Journal:  Clin Case Rep       Date:  2017-02-22

Review 10.  CSACI position statement: Newer generation H1-antihistamines are safer than first-generation H1-antihistamines and should be the first-line antihistamines for the treatment of allergic rhinitis and urticaria.

Authors:  Michael N Fein; David A Fischer; Andrew W O'Keefe; Gord L Sussman
Journal:  Allergy Asthma Clin Immunol       Date:  2019-10-01       Impact factor: 3.406

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.